Diebold Nixdorf Statistics
Total Valuation
DBD has a market cap or net worth of $1.76 billion. The enterprise value is $2.59 billion.
Important Dates
The next confirmed earnings date is Thursday, November 7, 2024, before market open.
| Earnings Date | Nov 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
DBD has 37.57 million shares outstanding. The number of shares has decreased by -45.45% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 37.57M |
| Shares Change (YoY) | -45.45% |
| Shares Change (QoQ) | +0.27% |
| Owned by Insiders (%) | 0.54% |
| Owned by Institutions (%) | 72.95% |
| Float | 27.06M |
Valuation Ratios
The trailing PE ratio is 0.94 and the forward PE ratio is 8.98.
| PE Ratio | 0.94 |
| Forward PE | 8.98 |
| PS Ratio | 0.52 |
| Forward PS | 0.45 |
| PB Ratio | 1.77 |
| P/FCF Ratio | 65.30 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 6.58, with an EV/FCF ratio of 95.93.
| EV / Earnings | 1.20 |
| EV / Sales | 0.68 |
| EV / EBITDA | 6.58 |
| EV / EBIT | 10.15 |
| EV / FCF | 95.93 |
Financial Position
The company has a current ratio of 1.42, with a Debt / Equity ratio of 1.09.
| Current Ratio | 1.42 |
| Quick Ratio | 0.70 |
| Debt / Equity | 1.09 |
| Debt / EBITDA | 2.34 |
| Debt / FCF | 40.75 |
| Interest Coverage | 1.44 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 4.40% |
| Return on Capital (ROIC) | 25.83% |
| Revenue Per Employee | $181,681 |
| Profits Per Employee | $103,076 |
| Employee Count | 21,000 |
| Asset Turnover | 1.05 |
| Inventory Turnover | 4.54 |
Taxes
In the past 12 months, DBD has paid $108.30 million in taxes.
| Income Tax | 108.30M |
| Effective Tax Rate | 4.76% |
Stock Price Statistics
The stock price has increased by +143.16% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +143.16% |
| 50-Day Moving Average | 44.10 |
| 200-Day Moving Average | 38.84 |
| Relative Strength Index (RSI) | 59.93 |
| Average Volume (20 Days) | 157,302 |
Short Selling Information
The latest short interest is 343,038, so 0.91% of the outstanding shares have been sold short.
| Short Interest | 343,038 |
| Short Previous Month | 343,511 |
| Short % of Shares Out | 0.91% |
| Short % of Float | 1.27% |
| Short Ratio (days to cover) | 2.15 |
Income Statement
In the last 12 months, DBD had revenue of $3.82 billion and earned $2.16 billion in profits. Earnings per share was $49.98.
| Revenue | 3.82B |
| Gross Profit | 906.50M |
| Operating Income | 255.20M |
| Pretax Income | -390.00M |
| Net Income | 2.16B |
| EBITDA | 393.90M |
| EBIT | 255.20M |
| Earnings Per Share (EPS) | $49.98 |
Full Income StatementBalance Sheet
The company has $285.40 million in cash and $1.10 billion in debt, giving a net cash position of -$814.90 million or -$21.69 per share.
| Cash & Cash Equivalents | 285.40M |
| Total Debt | 1.10B |
| Net Cash | -814.90M |
| Net Cash Per Share | -$21.69 |
| Equity (Book Value) | 1.01B |
| Book Value Per Share | 26.53 |
| Working Capital | 563.70M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $49.10 million and capital expenditures -$22.10 million, giving a free cash flow of $27.00 million.
| Operating Cash Flow | 49.10M |
| Capital Expenditures | -22.10M |
| Free Cash Flow | 27.00M |
| FCF Per Share | $0.72 |
Full Cash Flow StatementMargins
Gross margin is 23.76%, with operating and profit margins of 6.69% and 56.73%.
| Gross Margin | 23.76% |
| Operating Margin | 6.69% |
| Pretax Margin | 59.62% |
| Profit Margin | 56.73% |
| EBITDA Margin | 10.32% |
| EBIT Margin | 6.69% |
| FCF Margin | -8.89% |
Dividends & Yields
DBD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 45.45% |
| Shareholder Yield | 45.45% |
| Earnings Yield | 122.78% |
| FCF Yield | 1.53% |
Dividend DetailsAnalyst Forecast
The average price target for DBD is $57.50, which is 22.52% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $57.50 |
| Price Target Difference | 22.52% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
DBD has an Altman Z-Score of 1.63 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.63 |
| Piotroski F-Score | 4 |